



**86-10-6598-3166**

*Registrant's telephone number, including area code*

---

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

**Item 8.01 Other Events.**

On October 20, 2015, China Biologic Products, Inc. (the “Company”) issued a press release announcing that, on October 19, 2015, its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., received the operating permit from local authorities to commence plasma collection at the new branch collection facility in Zaozhuang City, Shandong Province. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

**Exhibit Number Description**

99.1 Press release issued by the Company dated October 20, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 20, 2015 CHINA BIOLOGIC  
PRODUCTS, INC.

By: /s/ David (Xiaoying) Gao  
David (Xiaoying) Gao  
Chief Executive Officer